Article
ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Apr 2012
Chapman Colby M, Sun Xiameng, Roschewski Mark, Aue Georg, Farooqui Mohamed, Stennett Lawrence, Gibellini Federica, Arthur Diane, Pérez-Galán Patricia, Wiestner Adrian
Abstract excerpt
PURPOSE: Chronic lymphocytic leukemia (CLL), a malignancy of mature B cells, is incurable with chemotherapy. Signals from the microenvironment support leukemic cell survival and proliferation and may confer chemotherapy resistance. ON 01910.Na (Rigosertib), a multikinase phosphoinositide 3-kinase (PI3K) inhibitor, is entering phase III trials for myelodysplastic syndrome. Our aim was to analyze the efficacy of ON...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.